They do certainly need to meet their projections for revenue from the Epi-Lasek device, because the LAD has not met any in the past, and seems to be on the proverbial slow boat to China. The LAD appears to be an excellent device and must be a winner in the paediatrics field, but take up elsewhere is not happening very fast . This report below confirmed for me that the LAD is not going to be a significant $ earner (almost certainly the reason for the companies poor share price over the last 18 mths or so imho ) where as the Epi-LASIK Centurion SES eyecare device looks set to earn substantial revenues. The jewel in the crown still appears to be Immunology, infact it is the only reason for me remaining a shareholder.
Norwood Abbey advises that the Cohen Independent Research Group based in the USA, have released a detailed commissioned independent research report on Norwood Abbey.
